THYKIOM : Thykamine anti-inflammatory and antioxidant mechanisms

The inflammation triggered by oxidative stress is the cause of many diseases, including atherosclerosis, chronic obstructive pulmonary disease, Alzheimer disease and cancer. Although numerous molecules evaluated as antioxidants have exhibited therapeutic potential in preclinical studies, clinical trial results have been mixed. A greater understanding of the mechanisms through which antioxidants act and where and when they are effective will provide a rational approach that leads to greater pharmacological success.

The Devonian health group (http://groupedevonian.com) is a late stage botanical pharmaceutical corporation with novel approaches to target unmet medical needs. Devonian’s strategy is to develop botanical drugs and novel pharmaceutical products from plant materials according to the Food Drugs Administration (FDA) set of regulatory guidelines to favor a more efficient drug development pathway. Among Devonian’s products, ThykamineTM is an active lead drug candidate with excellent safety and efficacy profiles towards inflammation. The molecular targets of Thykamine are currently unknown. Uncovering its mechanism of action would unravel Thykamine’s full potential, leading to its usage as treatment for several inflammatory-related diseases.

The project aims to identify the molecular targets of Thykamine specifically related to antioxidant and antiinflammatory properties to broaden its field of applications.

Faculty Supervisor:

Isabel Desgagné-Penix

Student:

Partner:

Devonian

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services

University:

Université du Québec à Trois-Rivières

Program: